HerAnova Lifesciences
PrivateLast Round
Seed
Dec 28, 2023
Total Funding Raised
$13.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
HerAnova Lifesciences operates in Healthcare & Life Sciences and is based in Burlington, Massachusetts. Its latest recorded funding round was a Seed round in December 2023.
HerAnova Lifesciences is a biotechnology company that develops non-invasive diagnostics and integrated care solutions for women's health, with a focus on endometriosis and infertility.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine
Business Model
B2B2C
Customer Profile
Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HerAnova Lifesciences Comparables
Compare HerAnova Lifesciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DotLab | 91% | |
| Hera Biotech | 87% | |
| NextGen Jane | 81% |
For institutional investors. Book with your work email.
HerAnova Lifesciences Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HerAnova Lifesciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Emerging Technology Partners | Seed |
| Triwise Capital | Seed |
| Sinovation Ventures | Seed |
| Pivotal bioVenture Partners China | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 116% MoM.
- Jun 19, 2026
Monthly visitors increased 30% MoM, reaching 3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asNov 4, 2026
Health Tech World names Heranova Lifesciences Inc. Femtech Company of the Year at the Health Tech World Awards 2026 on Oct 28th '26, recognizing its innovative work addressing unmet needs in women’s health.
- attends_eventNov 4, 2026
Heranova Lifesciences Inc. is named Femtech Company of the Year at the Health Tech World Awards 2026, with its Chief Medical Officer accepting the award at the Oct 28th '26 ceremony.
For institutional investors. Book with your work email.
HerAnova Lifesciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HerAnova Lifesciences's valuation, stock price, and market status.
Is HerAnova Lifesciences a public or private company?
HerAnova Lifesciences is a private company.
What is the current stock price of HerAnova Lifesciences?
HerAnova Lifesciences is a private company, so its shares have no public market price. Caplight tracks HerAnova Lifesciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HerAnova Lifesciences worth (valuation)?
Valuation information for HerAnova Lifesciences is not publicly available.
Can I buy HerAnova Lifesciences stock?
HerAnova Lifesciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HerAnova Lifesciences's last funding round?
HerAnova Lifesciences's most recent funding round was Seed on December 28, 2023.
Who are the main investors in HerAnova Lifesciences?
Key investors in HerAnova Lifesciences include Emerging Technology Partners, Triwise Capital, Sinovation Ventures, Pivotal bioVenture Partners China.
Will HerAnova Lifesciences IPO soon?
No public IPO plans have been announced for HerAnova Lifesciences.
How can I track HerAnova Lifesciences secondary market activity?
Caplight tracks bids, offers, and trades in HerAnova Lifesciences's shares on secondary markets.